Angiotensin-Neprilysin Inhibitor Therapy: A Retrospective Chart Study by Roda Plakogiannis, Abraham Stefanidis, Nubriel Hernandez, Etty Vider

“…Future studies should address diuretic dose adjustment in conjunction with the administration of ARNI and sodium-glucose cotransporter-2 inhibitors. …”
Get full text

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes by Bethany Murphy, Simran Chahal, Elleigh Shepherd, Nicole Taylor, Austin Camp

“…Purpose: In the treatment of type 2 diabetes mellitus (T2DM), select sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are recommended based on comorbidities such as chronic kidney disease (CKD), heart failure (HF), and atherosclerotic cardiovascular disease (ASCVD). …”
Get full text

Endothelial AGGF1 promotes retinal angiogenesis by coordinating TNFSF12/FN14 signalling by Ying Cheng, Man Zhang, Chenguang Li, Long Su, Lingli Fu, Shi Wu, Chaofei Xu, Bei Sun, Liming Chen

“…Additionally, we discover that sodium-glucose cotransporter 2 inhibitors (SGLT2i) could inhibit the AGGF1 signalling pathway early to achieve therapeutic effects. …”
Get full text

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature by Silvia Ciraolo, Agnieszka Kulczycka-Rowicka, Joanna Wojda, Katarzyna Lesiczka-Fedoryj, Anna Walczak, Zuzanna Kościuszko, Adam Sobiński, Matylda Czerwonka, Katarzyna Kurza, Julianna Podolec

“…The development of sodium-glucose cotransporter 2 (SGLT2) inhibitors has shown promising cardiovascular and renal benefits beyond glucose control. …”
Get full text

Prescription pattern, glycemic control status, and predictors of poor glycemic control among diabetic patients with comorbid chronic kidney disease in Ethiopia: a facility-based cr... by Oumer Sada Muhammed, Minimize Hassen, Samuel Mamusha

“…Insulin, metformin, and sodium glucose cotransporter-2 (SGLT-2) inhibitors were the most frequently prescribed anti-diabetic drug classes which accounted for 80.2%, 59.1%, and 41.4%, respectively. …”
Get full text

Temporal trends in guideline-recommended medical therapy after an acute heart failure decompensation event: an observational analysis from Generator Heart Failure DataMart by Antonio Gasbarrini, Giuseppe Patti, Filippo Crea, Giovanni Scambia, Domenico D'Amario, Vincenzo Valentini, Gianluigi Savarese, Alfredo Cesario, Jacopo Lenkowicz, Stefano Patarnello, Renzo Laborante, Agni Delvinioti, Andrada Mihaela Tudor, Chiara Iacomini, Antonio Iaconelli, Donato Antonio Paglianiti, Mattia Galli, Daniele Rodolico, Attilio Restivo, Giuseppe Ciliberti, Gaetano Rizzo, Emiliano Bianchini, Matteo Busti, Luca Sensini

“…The entire cohort was divided into three time periods based on two time points: September 2021 (ie, the release of the latest European guidelines) and January 2022 (ie, reimbursement for sodium-glucose cotransporter 2 (SGLT2) inhibitors).Primary and secondary outcome measures Trends and predictors of the prescription of each of the four foundational therapies and of the composite of all-cause death and rehospitalisation for urgent causes at 30 days.Results Among the 999 included patients, β-blockers were prescribed in 93% of patients, ACE inhibitor (ACEi)/angiotensin receptor blocker (ARB)/angiotensin–neprilysin receptor inhibitor (ARNi) in 73%, mineralocorticoid receptor antagonist in 30% and SGLT2 inhibitors in 18%. …”
Get full text